Granules India Ltd., a vertically integrated pharmaceutical company, announced a robust financial performance for the quarter and financial year ended March 31, 2026. The company reported a 23% year-on-year increase in revenue from operations for Q4FY26, amounting to ₹14,706 million.
The company’s EBITDA for the quarter rose by 40% year-on-year to ₹3,521 million, while the profit before tax (PBT) before exceptional items increased by 48% to ₹2,464 million. The net profit after tax (PAT) for the quarter stood at ₹2,016 million, marking a 33% year-on-year growth.
On an annual basis, Granules India‘s revenue from operations reached ₹53,656 million, a 20% increase compared to the previous year. The EBITDA for FY26 was ₹11,851 million, reflecting a 25% growth, while the PBT before exceptional items was ₹7,950 million, up by 26% year-on-year. The PAT for the year was ₹5,950 million, a 19% increase from FY25.
The revenue share from North America decreased to 72% in Q4FY26 from 79% in the same quarter last year, while the share from Europe increased to 17% from 8%. The company’s revenue from finished dosages, active pharmaceutical ingredients, pharmaceutical formulation intermediates, and peptides/CDMO contributed 73%, 13%, 9%, and 5% respectively in Q4FY26.
Granules India also reported an improvement in return on capital employed (ROCE), which rose to 17.6% in FY26 from 16.6% in FY25. The company’s net debt reduced by ₹3,040 million from Q4FY25, standing at ₹4,021 million, with a net debt to EBITDA ratio of 0.34x.
Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, commented on the results, stating that the strong performance was driven by portfolio expansion, disciplined execution, and progress in regulatory, compliance, and sustainability initiatives.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).